Eric C. Greig

Eric's experience includes advising:

Regulatory Advocacy

• A regional healthcare provider system on establishing a “hospital at home” program to deliver inpatient-level care to patients in their homes during the COVID-19 public health emergency (PHE)
• A publicly traded global life sciences company on: 
  • Expanding national Medicare coverage policies for continuous glucose monitoring (CGM) systems
  • Advocacy to successfully reverse a proposed Medicare payment reduction to CGMs 
• A leading national dialysis organization on modifying a value-based care payment model from the Center for Medicare and Medicaid Innovation (CMMI)
• A non-opioid drug manufacturer on coordinating a government affairs strategy that established new Medicare add-on payment pathways for non-opioid pain management treatments used in hospitals and ASCs
• A publicly traded medical technology company on reversing negative Medicare coverage policies for procedures involving the company’s flagship glaucoma treatment technology 
• A group of government agencies in the Middle East, on:
  • Designing and implementing an innovative, value-based healthcare ecosystem 
  • Drafting laws and regulations governing the structure of a new health insurance and reimbursement system
• Multiple Israel-based healthcare and life sciences companies on:
  • Healthcare regulatory counseling related to US-based clinical trial and commercialization matters
  • Reimbursement and market access strategy for the launch of molecular diagnostic tests 
• A nonprofit clinical trade association on reversing Medicare coverage policies that would have created barriers to patient access to advanced wound care therapies
• A leading healthcare services provider on activity within the provider’s venture investment division 
• The Coalition of Manufacturers of Speech Generating Devices on favorably expanding the scope of a Medicare National Coverage Determination (NCD)
• A group of pharmaceutical manufacturers on finalizing appropriate Medicare payment policies for novel drugs approved through FDA’s 505(b)(2) pathway

New Product Recognition

• AppliedVR, a digital health company focused on virtual reality-based solutions to treat chronic pain, on obtaining Medicare recognition, unique coding, and appropriate payment for its breakthrough VR device 
• The developer of a breakthrough treatment for advanced metastatic cancer on obtaining New Technology APC designation and payment for an algorithm-based treatment planning procedure and advanced radiation therapy delivery procedure performed with the company’s technology
• Magnus Medical on market access activities for the company’s novel brain stimulation technology for treatment-resistant major depressive disorder
• Cala Health, a leader in bioelectronic medicine, on establishing unique coding, preferred payment, and national Medicare coverage for its advanced neuromodulation system to treat Parkinson’s disease and essential tremor symptoms
• The developer of an AI-based diagnostic software solution on obtaining New Technology Add-on Payment (NTAP) and commercializing the product 
• Vektor Medical on establishing a new CPT code to report its machine-learning algorithm for noninvasive cardiac analysis
• A precommercial medical device manufacturer on obtaining coverage for its clinical trial procedures under Medicare’s Category B IDE Trial NCD
• A medical device company on achieving new coding and desired payment levels after an initial denial of insurance recognition for its product due to its app-based mechanism of action
• Multiple pharmaceutical manufacturers on obtaining new codes and establishing coverage for infused and injected products

Transactions

• Patient Square Capital on its:
  • US$1.25 billion acquisition of Hanger
  • US$300 million acquisition of SOC Telemed
  • Acquisition of Summit BHC
• KKR on its:
  • US$2.8 billion acquisition of WebMD
  • US$1.4 billion acquisition of PharMerica
  • Acquisition of Covenant Surgical Partners
• Leonard Green & Partners on its:
  • US$2.2 billion acquisition of ExamWorks Group
  • Purchase of a majority stake in MDVIP
• US Renal Care on its: 
  • Acquisition of DSI Renal
  • Sale to a private investor group led by Bain Capital
• Access TeleCare on acquiring Forefront Telecare
• Galen Partners on acquiring Wings Recovery Holdings
• BlueSprig Holdings, a KKR portfolio company, on acquiring Trumpet Behavioral Health

Litigation and Investigations

• A cardiac monitoring device manufacturer on obtaining a declination from DOJ following an investigation into the company’s referral relationships and market access activities
• A leading academic medical center on responding to an OIG audit and reducing alleged overpayment liability by more than 80%
• A group of nationally recognized hospitals on False Claims Act litigation related to Medicare claims involving cardiac rhythm devices
• A large health system on complying with the obligations of a corporate integrity agreement with the DOJ and HHS OIG
• A national network of oncology treatment centers on obtaining a declination from DOJ on an investigation into coding and billing practices and practice management fee arrangements